OCS™ Lung TOP Registry For Donor Lungs for Transplantation

NCT ID: NCT03639025

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

458 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-10

Study Completion Date

2029-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-arm, prospective, multi-center, post-approval U.S. registry

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an all-comers registry that will enroll:

1. Patients who receive OCS™ preserved double lung transplants from either standard criteria donors or donors initially deemed unacceptable; and
2. Patients who receive a single lung transplant from OCS™ preserved lung pairs from either standard criteria donors or donors initially deemed unacceptable; and
3. All donor lungs that were perfused on OCS Lung System.

Enrolled patients will fall into one of the following three possible analysis categories:

1. TOP SCDL PAS Primary Analysis Population: will be comprised of recipients transplanted with SCDL primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
2. TOP DLIDU Primary Analysis Population: Will be comprised of recipients transplanted with DLIDU primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
3. All Other Enrolled Patients: will be comprised of all OCS Lung transplanted patients in the TOP Registry that do not meet any of the above analysis populations.

Patient enrollment in the TOP Registry will continue until 266 eligible DLIDU Primary Analysis Population recipients have been enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Donor Lungs Primary Analysis Population

Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.

OCS Lung System

Intervention Type DEVICE

The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:

* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.
* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.
* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.

Donor Lungs Initially Unacceptable Primary Analysis Pop.

Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.

OCS Lung System

Intervention Type DEVICE

The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:

* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.
* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.
* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.

All Other Enrolled Patients

All OCS Lung transplanted patients that do not meet any of the above analysis populations.

OCS Lung System

Intervention Type DEVICE

The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:

* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.
* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.
* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OCS Lung System

The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:

* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.
* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.
* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TOP DLIDU Primary Analysis Population: Will be comprised of recipients transplanted with DLIDU primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
* All Other Enrolled Patients: will be comprised of all OCS Lung transplanted patients in the TOP Registry that do not meet any of the above analysis populations.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TransMedics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Site Status

UCLA

Los Angeles, California, United States

Site Status

Stanford University

Palo Alto, California, United States

Site Status

UCSF

San Francisco, California, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Emory

Atlanta, Georgia, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Johns Hopkins

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Temple University

Philadelphia, Pennsylvania, United States

Site Status

Baylor Scott & White Research Institute

Dallas, Texas, United States

Site Status

Baylor St. Luke's Medical Center

Houston, Texas, United States

Site Status

Houston Methodist

Houston, Texas, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OCS-LUN-PAS01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RELIVE Informed Consent Study
NCT01742234 COMPLETED
A2 to O Lung Transplants
NCT05581745 RECRUITING NA
LAMBDA 002 (Lung Registry) Study
NCT05170425 ACTIVE_NOT_RECRUITING